Things appear to be picking up at Glenmark Pharmaceuticals Limited’s innovation spin-out, Ichnos Sciences, Inc., with the US-headquartered firm striking its first licensing deal with Almirall S.A. for an IL-1RAP antagonist (ISB 880) in autoimmune disease.
Further, promising early data for a bispecific antibody in multiple myeloma presented at the 63rd American Society of Hematology (ASH)...